Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

By Sae-Won Han, Tae‐You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung and 6 more. Journal of Clinical Oncology, 2005

789 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/259ef15388b478971f480de187db90945e3fdb48

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. J. Chmielecki

In Pulmonary and Respiratory Medicine

1. J. Chmielecki
2. William Pao

Citations in the corpus

• Erlotinib in lung cancer - molecular and clinical predictors of outcome. (2005, neutral): “<5% 210 (65) 84 (67) 116 (66) 486 (67) ≥5% 99 (30) 34 (27) 47 (26) 213 (29) Data missing 16 (5) 7 (6) 14 (8) 32 (4)”
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009, neutral): “In four single-arm studies of EGFR TKIs in patients with metastatic NSCLC, a significantly longer overall survival was observed in patients with EGFR mutations (Cortez-Funes et al., 2005; Han et al., 2005; Mitsudomi et al., 2005; Takano et al., 2005).”
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “A small proportion (1–20%, depending on the trial) of patients with no detectable EGFR -activating mutations show a radiographic response when treated with EGFR TKI”